Home › phase
 

Keywords :   


Tag: phase

Avcorp secures firm orders from Lockheed for F-35 CV OBW production phase

2016-04-21 01:00:00| Naval Technology

Canada-based Avcorp Industries has secured firm orders from Lockheed Martin for the manufacturing of the F-35 Carrier Variant Outboard Wing (CV OBW) integrated assembly.

Tags: production orders firm phase

 

Ultra-Low Phase Noise OCXO XO5085-160MHz Datasheet

2016-04-20 16:39:28| rfglobalnet Home Page

The new Ultra-Low Phase Noise OCXO – XO5085-160MHz from MtronPTI is one of the lowest phase noise OCXOs in the industry. The OCXO – XO5085-160MHz consumes less than 4 Watts of power has tight stability, low-g sensitivity, and low aging, and is available over full industrial temperature range. This device can be used in high performance test and measurement, SATCOM, and Radar applications.

Tags: phase noise datasheet phase noise

 
 

Ultra-Low Phase Noise OCXO XO5085-160MHz

2016-04-20 16:34:56| rfglobalnet Home Page

The new Ultra-Low Phase Noise OCXO – XO5085-160MHz from MtronPTI is a new addition to their frequency control and timing products. As one of the lowest phase noise OCXOs in the industry, this device is available at 160 MHz nominal frequency range.

Tags: phase noise phase noise ultralow

 

Application Phase for Fifth Volkswagen and BASF \"Science Award Electrochemistry\" ...

2016-04-20 07:00:00| Coatings World Breaking News

Tags: science application phase award

 

Merck Announces Results From Phase 3 Studies of ZEPATIER (Elbasvir and Grazoprevir) in Chronic Hepatitis C Patient Populations at The International Liver Congress

2016-04-16 07:00:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from two Phase 3 clinical trials evaluating ZEPATIER (elbasvir and grazoprevir) 50mg/100mg tablets in chronic hepatitis C (HCV) patients with inherited blood disorders (C-EDGE IBLD) and in patients with a history of intravenous drug use who are receiving opioid agonist therapy (C-EDGE CO-STAR), respectively. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Sarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: the results international studies

 

Sites : [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] next »